Pacer Advisors Inc. Invests $3.45 Million in Emergent Biosolutions Inc. $EBS

Pacer Advisors Inc. bought a new stake in Emergent Biosolutions Inc. (NYSE:EBS) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 416,191 shares of the biopharmaceutical company’s stock, valued at approximately $3,454,000.

Other hedge funds also recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in Emergent Biosolutions in the 2nd quarter valued at $31,000. Torren Management LLC purchased a new position in Emergent Biosolutions during the 4th quarter worth $37,000. CANADA LIFE ASSURANCE Co bought a new stake in shares of Emergent Biosolutions in the 4th quarter worth $45,000. Raymond James Financial Inc. bought a new stake in shares of Emergent Biosolutions in the 2nd quarter worth $53,000. Finally, Farther Finance Advisors LLC raised its holdings in shares of Emergent Biosolutions by 361.3% in the fourth quarter. Farther Finance Advisors LLC now owns 6,163 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 4,827 shares during the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Wall Street Analyst Weigh In

EBS has been the topic of a number of recent analyst reports. Benchmark reissued a “buy” rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. Weiss Ratings downgraded shares of Emergent Biosolutions from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday, May 11th. Finally, UBS Group reiterated a “buy” rating on shares of Emergent Biosolutions in a research note on Tuesday, June 2nd. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Emergent Biosolutions has a consensus rating of “Hold” and an average target price of $12.00.

Trending Headlines about Emergent Biosolutions

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Second-quarter results exceeded expectations: Emergent reported adjusted EPS of $0.60, compared with the consensus estimate of a $0.08 loss, while revenue reached $234.3 million versus expectations of $177.5 million. Emergent Biosolutions: Q2 Earnings Snapshot
• Positive Sentiment: Biodefense demand remains a potential long-term catalyst: The company highlighted increased government and public-health attention to biological threats, including geopolitical conflict, synthetic biology and the possible misuse of biological agents. Cross-Sector Collaboration Against Biological Threats
• Neutral Sentiment: Management is undertaking a restructuring: The plan is part of broader turnaround efforts and includes layoffs, signaling an attempt to reduce costs and improve operating performance, but it may also create near-term disruption and expenses. Emergent BioSolutions Announces Restructuring
• Negative Sentiment: Full-year revenue guidance was cut well below analyst expectations: Emergent now expects 2026 revenue of $645 million to $675 million, compared with the consensus estimate of approximately $730.4 million. Emergent BioSolutions Shares Plunge After 2026 Guidance Cut
• Negative Sentiment: Third-quarter guidance was also materially below expectations: Revenue is projected at $110 million to $130 million, versus analyst expectations of about $209 million. The weak forward outlook and workforce reductions are driving the negative investor reaction despite the quarterly beat. Emergent Bio Slips Despite Q2 Beat After Guidance Cut

Emergent Biosolutions Stock Performance

NYSE EBS opened at $5.31 on Friday. The company has a market capitalization of $273.97 million, a PE ratio of -1.50 and a beta of 2.35. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.08 and a current ratio of 4.29. Emergent Biosolutions Inc. has a 52-week low of $5.06 and a 52-week high of $14.06. The company has a 50-day simple moving average of $7.90 and a 200 day simple moving average of $8.79.

Emergent Biosolutions (NYSE:EBS) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 14.83%. The firm had revenue of $234.30 million for the quarter, compared to analysts’ expectations of $177.50 million.

Insider Activity at Emergent Biosolutions

In related news, SVP Paul Anthony Williams sold 3,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $8.40, for a total value of $25,200.00. Following the transaction, the senior vice president owned 159,098 shares in the company, valued at approximately $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.00% of the company’s stock.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.